PHILADELPHIA (WPVI) -- The FDA is investigating an alarming finding on a promising cancer therapy invented at Penn Medicine. It's being linked to rare, secondary cancers. The agency said it received ...
In 2010, Doug Olson became the second person in the world to receive CAR-T cell therapy, an experimental tactic to engineer his own immune cells to fight cancer. His doctors had tempered expectations ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...
As cancer-killing CAR-T cells course through the body, they make occasional pit stops at the gut. What they do there — and which gut microbes they meet up with — could potentially change the prospects ...
In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma. Researchers sought to determine whether ...
A new literature review explores the emerging application of CAR-T cell therapy in treating people with Systemic Lupus Erythematosus (SLE). Preliminary data suggests that CAR-T therapy may ...
The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) – a CAR-T cell therapy – for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma ...
Never in their wildest dreams dreams would immunologists from the last generation have imagined chimeric antigen receptor (CAR)-T cell therapy coming to light. The very notion of genetically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results